NASDAQ

Bioventus Inc. - Class A (BVS)

538 Thanks from members

Bioventus Inc. (BVS) exhibits positive financial momentum with Q2 2026 revenue of $153.2 million, beating EPS estimates at $0.22, and reaffirming full-year guidance while initiating a strategic alternatives review.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →